Rie Schultz Hansen

Rie Schultz Hansen is an accomplished scientific leader with extensive experience in the biotechnology sector. Currently serving as the Chief Scientific Officer at Augustine Therapeutics since May 2025, Rie also operates as a self-employed company owner from August 2024. Prior to these roles, Rie held the position of Chief Scientific Officer at Aelin Therapeutics from August 2022 to September 2024 and was Vice President at Zealand Pharma A/S from September 2019 to August 2022, where responsibilities included Head of Discovery and Innovation and Interim Chief Scientific Officer. Rie holds a PhD in Cardiac Electrophysiology and an MSc in Biology, both from Københavns Universitet - University of Copenhagen.